Medical management of extrathyroidal manifestation of graves disease

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

To review preventive measures and the current medical management of extrathyroidal manifestation of Graves disease and to provide an overview of potential immune therapies.Methods: A literature review of investigative trials of treatments for Graves disease and its extrathyroidal manifestations.Results: Given new knowledge of the stages of the autoimmune cascade responsible for the development of these extrathyroidal manifestations, the possibility has been raised of performing randomized trials of agents shown to provide benefits in other immune conditions. Two randomized trials on the efficacy of rituximab in moderate-to-severe Graves ophthalmopathy have reported conflicting results.Conclusion: Additional studies of rituximab and other agents are needed before they become routinely used in treating Graves disease. Meanwhile, the standard medical therapy for moderate-to-severe ophthalmopathy is intravenous (IV) or oral corticosteroids and, for dermopathy, local corticosteroid application with occlusive dressing. Because major adverse effects such as life-threatening hepatic failure can occur with very high doses of IV prednisolone, the cumulative total dose should not exceed 8 g.

Original languageEnglish (US)
Pages (from-to)1333-1344
Number of pages12
JournalEndocrine Practice
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Graves Disease
Adrenal Cortex Hormones
Occlusive Dressings
Graves Ophthalmopathy
Liver Failure
Prednisolone
Therapeutics
Rituximab

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Medical management of extrathyroidal manifestation of graves disease. / Fatourechi, Vahab.

In: Endocrine Practice, Vol. 20, No. 12, 01.12.2014, p. 1333-1344.

Research output: Contribution to journalReview article

@article{601862e3630d49c386180e3b6585ca68,
title = "Medical management of extrathyroidal manifestation of graves disease",
abstract = "To review preventive measures and the current medical management of extrathyroidal manifestation of Graves disease and to provide an overview of potential immune therapies.Methods: A literature review of investigative trials of treatments for Graves disease and its extrathyroidal manifestations.Results: Given new knowledge of the stages of the autoimmune cascade responsible for the development of these extrathyroidal manifestations, the possibility has been raised of performing randomized trials of agents shown to provide benefits in other immune conditions. Two randomized trials on the efficacy of rituximab in moderate-to-severe Graves ophthalmopathy have reported conflicting results.Conclusion: Additional studies of rituximab and other agents are needed before they become routinely used in treating Graves disease. Meanwhile, the standard medical therapy for moderate-to-severe ophthalmopathy is intravenous (IV) or oral corticosteroids and, for dermopathy, local corticosteroid application with occlusive dressing. Because major adverse effects such as life-threatening hepatic failure can occur with very high doses of IV prednisolone, the cumulative total dose should not exceed 8 g.",
author = "Vahab Fatourechi",
year = "2014",
month = "12",
day = "1",
doi = "10.4158/EP14281.RA",
language = "English (US)",
volume = "20",
pages = "1333--1344",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "12",

}

TY - JOUR

T1 - Medical management of extrathyroidal manifestation of graves disease

AU - Fatourechi, Vahab

PY - 2014/12/1

Y1 - 2014/12/1

N2 - To review preventive measures and the current medical management of extrathyroidal manifestation of Graves disease and to provide an overview of potential immune therapies.Methods: A literature review of investigative trials of treatments for Graves disease and its extrathyroidal manifestations.Results: Given new knowledge of the stages of the autoimmune cascade responsible for the development of these extrathyroidal manifestations, the possibility has been raised of performing randomized trials of agents shown to provide benefits in other immune conditions. Two randomized trials on the efficacy of rituximab in moderate-to-severe Graves ophthalmopathy have reported conflicting results.Conclusion: Additional studies of rituximab and other agents are needed before they become routinely used in treating Graves disease. Meanwhile, the standard medical therapy for moderate-to-severe ophthalmopathy is intravenous (IV) or oral corticosteroids and, for dermopathy, local corticosteroid application with occlusive dressing. Because major adverse effects such as life-threatening hepatic failure can occur with very high doses of IV prednisolone, the cumulative total dose should not exceed 8 g.

AB - To review preventive measures and the current medical management of extrathyroidal manifestation of Graves disease and to provide an overview of potential immune therapies.Methods: A literature review of investigative trials of treatments for Graves disease and its extrathyroidal manifestations.Results: Given new knowledge of the stages of the autoimmune cascade responsible for the development of these extrathyroidal manifestations, the possibility has been raised of performing randomized trials of agents shown to provide benefits in other immune conditions. Two randomized trials on the efficacy of rituximab in moderate-to-severe Graves ophthalmopathy have reported conflicting results.Conclusion: Additional studies of rituximab and other agents are needed before they become routinely used in treating Graves disease. Meanwhile, the standard medical therapy for moderate-to-severe ophthalmopathy is intravenous (IV) or oral corticosteroids and, for dermopathy, local corticosteroid application with occlusive dressing. Because major adverse effects such as life-threatening hepatic failure can occur with very high doses of IV prednisolone, the cumulative total dose should not exceed 8 g.

UR - http://www.scopus.com/inward/record.url?scp=84920025690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920025690&partnerID=8YFLogxK

U2 - 10.4158/EP14281.RA

DO - 10.4158/EP14281.RA

M3 - Review article

AN - SCOPUS:84920025690

VL - 20

SP - 1333

EP - 1344

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 12

ER -